Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

y the European Medicines Agency (the "EMA") based on the pixantrone (PIX 301) phase III study results.  

For more information on the PIX-R trial, investigators and patients can visit www.pixrtrial.com, and www.clinicaltrials.gov.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines--rather than intercalation with DNA--pixantrone alkylates DNA--forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert<
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe ... Italy , UK, Spain ) Summary GBI ... Europe ( Germany , France , ... analysis of the transcatheter heart valves market in Europe . ... period and key company share data by revenue in 2013 for the following ...
(Date:9/23/2014)... -- Report Details Where is the prostate cancer ... potential revenues to 2024, assessing data, trends, opportunities and ... charts, and graphs. Our new study lets you assess ... market, showing their prospects to 2024. Discover the most ... prospects. Our new study lets you assess forecasted sales ...
(Date:9/23/2014)... , Sept. 23, 2014  SI-BONE, Inc., a medical ... Implant System, ® a minimally invasive surgical (MIS) ... today announced that the U.S. Patent and Trademark Office ... and methods for the fixation and fusion of bone.  ... implant with a tapered distal end that may be placed from one ...
Breaking Medicine Technology:Market Snapshot: Transcatheter Heart Valve 2007 to 2020 - Europe (Germany, France, Italy, UK, Spain) 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 2The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 3The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 4The Prostate Cancer Therapeutics Market Forecast 2014-2024 : Opportunities for Leading Companies 5SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 2SI-BONE, Inc. Strengthens Patent Portfolio with the U.S. Patent and Trademark Office's Issuance of Threaded, Fenestrated Implant Method Patent 3
... a biotechnology company that develops targeted therapies for oncology ... results from studies of TRC105 and TRC102 in patients ... Society of Clinical Oncology annual meeting this May 28th ... pathways with the potential for broad application to a ...
... Confirm Tapentadol Efficacy and Tolerability for Acute Pain PatientsRARITAN, ... to 30 percent of all people who have surgery ... The use of opioid pain medicines during and after ... side effects. Nausea and vomiting are uncomfortable and bothersome ...
Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 3New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 4New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 5New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 6New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 7New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 8
(Date:9/23/2014)... Oakland, California (PRWEB) September 23, 2014 ... knows everything about cultivating, growing and harvesting marijuana. He ... innovators in the field and he’ll be leading a ... from 10:00 am to 5:00 pm at Oaksterdam ... cover cultivation law, botany and nomenclature, harvesting and manicuring, ...
(Date:9/23/2014)... ZEPHYRHILLS, FL (PRWEB) September 23, 2014 ... opening of the newly renovated Women’s Health Center ... square feet of space, the specially designed center ... women in East Pasco County. The Women’s Health ... and pelvic floor health, labor and delivery through ...
(Date:9/23/2014)... TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS ... WHAT: , The National Institutes of Health is convening ... scientific evidence on the long-term effectiveness and potential risks ... among the nation,s top experts in the field of ... well as key NIH scientists who focus on pain ...
(Date:9/23/2014)... September 24, 2014 From first-hand experience, ... (PTSD) – and how it can be treated. , ... in Iraq in 2006. His platoon sustained multiple attacks ... he was diagnosed with combat-related PTSD and honorably discharged ... angry, and I had distanced myself from my friends ...
(Date:9/23/2014)... Dr. Connie Casad has announced that she will be ... at 12200 Park Central Drive, Suite 200, Dallas, Texas 75251 ... Cities Aesthetics, Optimal Health and Wellness, her gynecology practice and ... Casad said, “The patients’ comfort and satisfaction are our primary ... to always feel like their needs are valued and recognized ...
Breaking Medicine News(10 mins):Health News:Special Elective Course Added to Oaksterdam University Schedule; Unique Opportunity to Learn From the “Godfather of Cannabis” Mel Frank on September 27, 2014 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Dr. Connie Casad Moving to New Office Location 2
... ... Geriatrics Association shows a new virtual reality device, the GaitAid, can help stroke patients learn to ... Haifa, Israel (PRWEB) February ... stroke each year. It is one of the leading causes of adult disability in the U.S. ...
... ATLANTA--A new study has found that many male cancer ... radiation therapy have an impaired quality of life and ... , a peer-reviewed journal of the American Cancer Society, ... testosterone deficiency may benefit from testosterone replacement therapy. ...
... , ... ... ... ...
... ... opens it newest location in beautiful Olde Towne Gaithersburg Maryland. Funeral Directors assist ... and multicultural community. , ... Gaithersburg, MD (PRWEB) February 21, 2010 -- A new, affordable option in funeral ...
... three million children have been born as a result of ... tube baby" in 1978. While the majority of these ... at greater risk of certain kinds of birth defects and ... and type 2 diabetes later in life. Carmen Sapienza, ...
... ... Lauderdale, now offers both the Cisco CCNA Security (prerequisite) and Cisco CCSP Certification Courses ... ... as a prerequisite course. These courses may now be taken at the warm ...
Cached Medicine News:Health News:New Successful Treatment Improves Walking Post Stroke 2Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 2Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 3Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 4Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 5Health News:Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service 2Health News:Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service 3Health News:Cisco CCSP Now Requires CCNA Security as Prerequisite 2Health News:Cisco CCSP Now Requires CCNA Security as Prerequisite 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: